Literature DB >> 16163424

[Promoter methylation profile in gastric cancer].

Juan Carlos Roa1, Leonardo Anabalón, Iván Roa, Oscar Tapia, Angélica Melo, Miguel Villaseca, Juan Carlos Araya.   

Abstract

BACKGROUND: Promoter genomic DNA methylation is an important inactivation mechanism of tumor suppressor genes. This genetic-molecular pathway for cancer may separate a subset of patients with different prognoses and eventually different responses to specific therapies. AIM: To analyze the methylation pattern of important genes related to different carcinogenic mechanisms in patients with gastric cancer (GC) and the relationship with its morphological features and biological behavior.
MATERIAL AND METHODS: Forty-seven fresh-frozen GC samples were selected. The methylation-specific PCR (MSP) test was used to analyze promoter methylation status for genes MLH1, CDKN2A (p16), APC, CDH1 (Cadherin E) and FHIT. Follow-up and complete morphological features were obtained for all cases.
RESULTS: We found methylation in at least one of the genes studied in 83% of the cases. The frequencies of promoter hypermethylation of MLH1, CDKN2A, APC, CDH1 and FHIT were 31%, 43%, 46%, 80% y 62%, respectively. We found a relationship between APC methylation and good histological differentiation (p =0.03); CDH1 methylation with diffuse type by Lauren and 3 or more metastasic lymph nodes (p <0.05); FHIT, CDKN2A and CDH1 methylation and female condition (p <0.04). We also found a non-significant relationship between CDKN2A methylation and better survival (p =0.07).
CONCLUSIONS: The high frequency promoter methylation found confirms its importance in gastric carcinogenesis. The finding of alterations in the methylation pattern of genes studied and its association with prognostic factors is a helpful tool in the search for new criteria in clinical and therapeutic decision making.

Entities:  

Mesh:

Year:  2005        PMID: 16163424     DOI: /S0034-98872005000800002

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  6 in total

1.  Predictive value of CHFR and MLH1 methylation in human gastric cancer.

Authors:  Yazhuo Li; Yunsheng Yang; Youyong Lu; James G Herman; Malcolm V Brock; Po Zhao; Mingzhou Guo
Journal:  Gastric Cancer       Date:  2014-04-21       Impact factor: 7.370

2.  Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil.

Authors:  Mariana Ferreira Leal; Eleonidas Moura Lima; Patrícia Natália Oliveira Silva; Paulo Pimentel Assumpção; Danielle Queiroz Calcagno; Spencer Luiz Marques Payão; Rommel Rodríguez Burbano; Marília Arruda Cardoso Smith
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

3.  p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer.

Authors:  Mohammad Reza Abbaszadegan; Omeed Moaven; Hamid Reza Sima; Kamran Ghafarzadegan; Azadeh A'rabi; Mohammad Naser Forghani; Hamid-Reza Raziee; Ali Mashhadinejad; Mostafa Jafarzadeh; Ehsan Esmaili-Shandiz; Ezzat Dadkhah
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

4.  Clinicopathological significance of E-cadherin, β-catenin and p53 expression in gastric adenocarinoma.

Authors:  Mohammad Reza Zali; Omeed Moaven; Hamid Asadzadeh Aghdaee; Kamran Ghafarzadegan; Khadijeh Jami Ahmadi; Mehdi Farzadnia; Azadeh Arabi; Mohammad Reza Abbaszadegan
Journal:  J Res Med Sci       Date:  2009-07       Impact factor: 1.852

5.  Hypermethylation and post-transcriptional regulation of DNA methyltransferases in the ovarian carcinomas of the laying hen.

Authors:  Jin-Young Lee; Wooyoung Jeong; Whasun Lim; Chul-Hong Lim; Seung-Min Bae; Jinyoung Kim; Fuller W Bazer; Gwonhwa Song
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

6.  Copy Number Gains at 8q24 and 20q11-q13 in Gastric Cancer Are More Common in Intestinal-Type than Diffuse-Type.

Authors:  Dong-Hao Jin; Seong-Eun Park; Jeeyun Lee; Kyung-Mi Kim; Sung Kim; Duk-Hwan Kim; Joobae Park
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.